Cargando…

Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System

In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single s...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsayed, Ibrahim, El-Dahmy, Rania Moataz, Elshafeey, Ahmed Hassen, Abd El Gawad, Nabaweya Abdelaziz, El Gazayerly, Omaima Naim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631901/
https://www.ncbi.nlm.nih.gov/pubmed/31212660
http://dx.doi.org/10.3390/pharmaceutics11060275
_version_ 1783435627145986048
author Elsayed, Ibrahim
El-Dahmy, Rania Moataz
Elshafeey, Ahmed Hassen
Abd El Gawad, Nabaweya Abdelaziz
El Gazayerly, Omaima Naim
author_facet Elsayed, Ibrahim
El-Dahmy, Rania Moataz
Elshafeey, Ahmed Hassen
Abd El Gawad, Nabaweya Abdelaziz
El Gazayerly, Omaima Naim
author_sort Elsayed, Ibrahim
collection PubMed
description In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single simple step was adopted for preparation, then the prepared formulations were investigated by analyzing their particle size (PS), polydispersity index (PDI), Zeta potential (ZP), entrapment efficiency (EE), and flowability properties. D-optimal design was applied to choose the optimized formulations. The maximum desirability values were 0.754 and 0.478 for the optimized formulations containing 0.05 g CA, 0.18 g T80, and 0.5 g mannitol (OFM) or Aerosil (OFA), respectively. In vitro drug release from the optimized formulations showed a significantly faster dissolution rate when compared to the market product. In vivo performance of the optimized formulations in rabbits was investigated after filling them into enteric-coated capsules. Ultimately, OFA formulation achieved a 3 times increase in RC oral bioavailability in comparison with the market product, supporting the hypothesis of considering IFNs as promising nanocarriers able to boost the bioavailability of BCS class II drugs.
format Online
Article
Text
id pubmed-6631901
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66319012019-08-19 Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System Elsayed, Ibrahim El-Dahmy, Rania Moataz Elshafeey, Ahmed Hassen Abd El Gawad, Nabaweya Abdelaziz El Gazayerly, Omaima Naim Pharmaceutics Article In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween(®) 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single simple step was adopted for preparation, then the prepared formulations were investigated by analyzing their particle size (PS), polydispersity index (PDI), Zeta potential (ZP), entrapment efficiency (EE), and flowability properties. D-optimal design was applied to choose the optimized formulations. The maximum desirability values were 0.754 and 0.478 for the optimized formulations containing 0.05 g CA, 0.18 g T80, and 0.5 g mannitol (OFM) or Aerosil (OFA), respectively. In vitro drug release from the optimized formulations showed a significantly faster dissolution rate when compared to the market product. In vivo performance of the optimized formulations in rabbits was investigated after filling them into enteric-coated capsules. Ultimately, OFA formulation achieved a 3 times increase in RC oral bioavailability in comparison with the market product, supporting the hypothesis of considering IFNs as promising nanocarriers able to boost the bioavailability of BCS class II drugs. MDPI 2019-06-11 /pmc/articles/PMC6631901/ /pubmed/31212660 http://dx.doi.org/10.3390/pharmaceutics11060275 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elsayed, Ibrahim
El-Dahmy, Rania Moataz
Elshafeey, Ahmed Hassen
Abd El Gawad, Nabaweya Abdelaziz
El Gazayerly, Omaima Naim
Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title_full Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title_fullStr Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title_full_unstemmed Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title_short Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System
title_sort tripling the bioavailability of rosuvastatin calcium through development and optimization of an in-situ forming nanovesicular system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631901/
https://www.ncbi.nlm.nih.gov/pubmed/31212660
http://dx.doi.org/10.3390/pharmaceutics11060275
work_keys_str_mv AT elsayedibrahim triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem
AT eldahmyraniamoataz triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem
AT elshafeeyahmedhassen triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem
AT abdelgawadnabaweyaabdelaziz triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem
AT elgazayerlyomaimanaim triplingthebioavailabilityofrosuvastatincalciumthroughdevelopmentandoptimizationofaninsituformingnanovesicularsystem